Etcembly Announces Breakthrough in Optimising TCR Assets
Oxfordshire, UK, 15 December 2022 – Etcembly, a tech-bio company transforming the precision, scale, and speed of development of T cell receptor (TCR) immunotherapies, today announced the successful prediction and optimisation of multiple TCR assets for targeting leukamias and solid tumours.
